

CITATION REPORT

List of articles citing

Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial

DOI: 10.1200/jco.2003.04.013

Journal of Clinical Oncology, 2003, 21, 428-32.

Source: <https://exaly.com/paper-pdf/35828168/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
322	The role of SPET and PET in monitoring tumour response to therapy. 2003 , 30, 1173-200		18
321	The role of radiation therapy in the treatment of esophagus cancer. 2003 , 1, 5-15		1
320	What's new in general thoracic surgery. 2003 , 197, 88-96		
319	Esophageal cancer. 2003 , 349, 2241-52		2304
318	Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4604-10	2.2	267
317	Imaging of esophageal cancer. 2004 , 4, 125-32		21
316	PET und PET/CT - Stellenwert beim Ösophaguskarzinom. 2004 , 27, 288-294		2
315	Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. <i>Journal of Clinical Oncology</i> , 2004 , 22, 900-8	2.2	382
314	Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. 2004 , 91, 666-72		45
313	Imaging of esophageal and gastric cancer. 2004 , 31, 530-41		72
312	Prediction of Response to Multimodality Treatment in Esophageal Cancer. 2004 , 3, 253-256		
311	Monitoring of Tumor Response to Neoadjuvant Radio-Chemotherapy of Esophageal Carcinoma by F-18-FDG-PET. 2004 , 3, 257-262		
310	Current status of esophageal cancer [West versus East: the European point of view. 2004 , 1, 147-159		6
309	The current status of esophageal cancer treatment in North America. 2004 , 1, 161-168		1
308	Analysis of gene expression profiles of hepatocellular carcinomas with regard to 18F-fluorodeoxyglucose uptake pattern on positron emission tomography. 2004 , 31, 1621-30		67
307	PET/CT molecular imaging in abdominal oncology. 2004 , 29, 388-97		14
306	Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction. 2004 , 100, 2347-54		61

305	2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. 2004 , 101, 1776-85	217
304	Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials. 2004 , 58, 1405-10	21
303	PET imaging in assessing gastrointestinal tumors. 2004 , 42, 1123-39, ix	24
302	Imaging for esophageal tumors. 2004 , 14, 61-9	27
301	Effects of neoadjuvant radio-chemotherapy on 18F-FDG-PET in esophageal carcinoma. 2004 , 30, 544-50	60
300	Positron emission tomography as a tool for translational research in oncology. 2004 , 6, 214-24	19
299	Noninvasive staging of esophageal carcinoma. 2004 , 117, 127-33	18
298	Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. 2004 , 78, 1152-60; discussion 1152-60	274
297	Neoplasms of the esophagus and stomach. 2004 , 34, 198-208	41
296	Bibliography. Current world literature. Inflammatory bowel disease. 2004 , 20, 404-22	
295	Positron emission tomography in gastric and esophageal cancer. 2004 , 16, 359-63	11
294	Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer. 2004 , 10, 243-50	25
293	Systemic treatment of oesophageal cancer. 2004 , 16, 249-54	3
292	Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). 2005 , 241, 810-7; discussion 817-20	122
291	Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. 2005 , 242, 684-92	281
290	FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. 2005 , 61, 129-36	183
289	The integration of 18-fluoro-deoxy-glucose positron emission tomography and endoscopic ultrasound in the treatment-planning process for esophageal carcinoma. 2005 , 61, 1123-8	121
288	FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. 2005 , 63, 1053-9	114

287	[Chemoradiation: an alternative to surgery for the curative treatment esophageal cancer?]. 2005 , 29, 551-6		3
286	The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. 2005 , 129, 1232-41		210
285	Diagnostic radiology and nuclear medicine. 2005 , 92, 191-202		7
284	The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. 2005 , 32, 918-24		105
283	[Prognostic factors in the evaluation of colorectal liver metastases]. 2005 , 76, 535-6, 538-42		2
282	[Neoadjuvant therapy for squamous cell carcinoma of the esophagus]. 2005 , 76, 1025-32		5
281	Positron emission tomography in esophageal cancer. 2005 , 2, 111-121		5
280	Current status of surgery for gastric cancer: a review. 2005 , 8, 64-70		64
279	Oncology Digestive Tract. 2005 , 137-151		
278	Targeted therapies for esophageal cancer. 2005 , 10, 590-601		114
277	Wertigkeit der Positronenemissionstomographie für das Staging beim Ösophaguskarzinom. 2005 , 40, 242-245		
276	Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy--systematic review. 2005 , 236, 841-51		235
275	PET for response assessment in oncology: radiotherapy and chemotherapy. 2005 , Supplement_28, 42-49		21
274	Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8362-70	2.2	221
273	Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 7445-53	2.2	232
272	Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. 2005 , 11, 2785-808		512
271	Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. 2005 , 35, 316-23		90
270	Glucose metabolism in brain tumours can be estimated using [18F]2-fluorodeoxyglucose positron emission tomography and a population-derived input function scaled using a single arterialised venous blood sample. 2005 , 26, 1377-83		10

269	Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. <i>Journal of Clinical Oncology</i> , 2005 , 23, 4330-7	2.2	366
268	Monitoring response to treatment in patients utilizing PET. 2005 , 43, 189-204		129
267	Systemic treatment for oesophageal cancer. 2005 , 41, 664-72		26
266	Neoadjuvant chemotherapy for oesophageal cancer: the need for accurate response prediction and evaluation. 2005 , 3, 373-82, 422		14
265	Imaging for Esophageal Tumors. 2005 , 43, 611-619		1
264	Role of positron emission tomography in the (re-)staging of oesophageal cancer. 2006 , 116-22		15
263	Gastrointestinal tract malignancies and positron emission tomography: an overview. 2006 , 36, 169-81		60
262	Cancer of the gastroesophageal junction: combined modality therapy. 2006 , 15, 803-24		14
261	Evolving role of (18)F-fluorodeoxyglucose positron emission tomography in the management of esophageal carcinoma. 2006 , 15, 733-49		6
260	Preoperative 18[F]-fluorodeoxyglucose positron emission tomography standardized uptake values predict survival after esophageal adenocarcinoma resection. 2006 , 81, 1076-81		102
259	Imaging response assessment in oncology. 2006 , 6, S126-30		45
258	Surgical management of esophagogastric junction tumors. <i>World Journal of Gastroenterology</i> , 2006 , 12, 6608-13	5.6	48
257	Expanding role of positron emission tomography in cancer of the uterine cervix. 2006 , 4, 463-9		11
256	Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed Tomographic-Positron Emission Tomographic Imaging. 2006 , 1, 478-486		20
255	Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. 2006 , 243, 472-8		131
254	Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy. 2006 , 21, 137-45		32
253	Is it time to incorporate quantitative functional imaging data, FDG PET in particular, into the response evaluation criteria in solid tumours?. 2006 , 27, 413-6		3
252	Interobserver and intraobserver variability of standardized uptake value measurements in non-small-cell lung cancer. 2006 , 21, 205-12		21

251	Influence of F-fluorodeoxyglucose-positron emission tomography on computed tomography-based radiation treatment planning for oesophageal cancer. 2006 , 50, 271-4	9
250	Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer. 2006 , 19, 273-6	22
249	The importance of PET in the diagnosis and response evaluation of esophageal cancer. 2006 , 19, 433-42	67
248	(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. 2006 , 95, 1174-9	102
247	Gastrointestinal malignancies evaluated with (18)F-fluoro-2-deoxyglucose positron emission tomography. 2006 , 20, 3-21	5
246	Response monitoring of neoadjuvant therapy using CT, EUS, and FDG-PET. 2006 , 20, 941-57	31
245	Staging in oesophageal cancer. 2006 , 20, 877-91	24
244	Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. 2006 , 13, 214-20	31
243	The growing pains of neoadjuvant trials for gastroesophageal carcinoma. 2006 , 13, 285-7	
242	Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. 2006 , 13, 1261-8	264
241	2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. 2006 , 8, 193-200	20
240	Role of positron emission tomography in decisions on treatment strategies for pancreatic cancer. 2006 , 13, 435-41	46
239	FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. 2006 , 33, 770-8	49
238	Monitoring chemotherapy and radiotherapy of solid tumors. 2006 , 33 Suppl 1, 27-37	100
237	Cancer of the gastroesophageal junction: Current therapy options. 2006 , 7, 410-23	7
236	[18F] fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography in response evaluation after chemo-/radiotherapy of non-small-cell lung cancer: a feasibility study. 2006 , 6, 51	88
235	Staging stenotic oesophageal tumours: are CT and/or PET enough? Dilate or not?. 2006 , 38 Suppl 1, S8-12	1
234	PET/CT of esophageal cancer: its role in clinical management. 2007 , 27, 1635-52	131

233	Functional PET imaging in cancer drug development. 2007 , 3, 215-28	16
232	Radiochemotherapy of esophageal cancer. 2007 , 2, 553-68	30
231	FDG-PET/CT tumor segmentation-derived indices of metabolic activity to assess response to neoadjuvant therapy and progression-free survival in esophageal cancer: correlation with histopathology results. 2007 , 30, 377-88	71
230	Esophageal cancer: adjuvant therapy. 2007 , 13, 162-7	9
229	Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. 2007 , 84, 393-400; discussion 400	57
228	PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. 2007 , 8, 797-805	632
227	PET-guided induction chemotherapy. 2007 , 8, 754-5	1
226	In Vivo Imaging of Cancer Therapy. 2007 ,	2
225	Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation. 2007 , 5, 97	13
224	PET/CT and hepatic radiation injury in esophageal cancer patients. 2007 , 7, 189-94	30
223	Detection of interval distant metastases: clinical utility of integrated CT-PET imaging in patients with esophageal carcinoma after neoadjuvant therapy. 2007 , 109, 125-34	90
222	Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. 2007 , 69, 358-63	42
221	Endoscopic ultrasound predicts outcomes for patients with adenocarcinoma of the gastroesophageal junction. 2007 , 205, 593-601	45
220	Considerations in treatment planning for esophageal cancer. 2007 , 17, 53-61	20
219	The role of integrated computed tomography positron-emission tomography in esophageal cancer: staging and assessment of therapeutic response. 2007 , 17, 29-37	42
218	The utility of positron emission tomography in staging of potentially operable carcinoma of the thoracic esophagus: results of the American College of Surgeons Oncology Group Z0060 trial. 2007 , 133, 738-45	109
217	Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery?. 2007 , 14, 2036-44	34
216	[18F-FDG-PET in therapy response of esophageal cancer]. 2007 , 47, 110-4	3

215	Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction. 2007 , 34, 1925-32	86
214	Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer. 2008 , 35, 1-4	11
213	Role of PET/PET CT in the staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: a literature review. 2008 , 33, 183-90	28
212	Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. 2008 , 184, 15-22	21
211	The evaluation of esophageal adenocarcinoma using dynamic contrast-enhanced magnetic resonance imaging. 2008 , 12, 166-75	32
210	Management of hepatic metastasis from colorectal cancers: an update. 2008 , 15, 570-80	55
209	Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. 2008 , 21, 151-8	58
208	Evaluation of clinical significance of 18F-fluorodeoxyglucose positron emission tomography in superficial squamous cell carcinomas of the thoracic esophagus. 2008 , 21, 144-50	23
207	Place de la TEP pour prédire la réponse métabolique précoce et guider le traitement des adénocarcinomes de la jonction œsogastrique : Étude de phase II MUNICON. 2008 , 145, 79	
206	Are patients with esophageal cancer who become PET negative after neoadjuvant chemoradiation free of cancer?. 2008 , 206, 879-86; discussion 886-7	41
205	Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. 2008 , 136, 205-12, 212.e1-3	41
204	Use of (18)F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. 2008 , 144, 793-802	41
203	Imaging and cancer: a review. 2008 , 2, 115-52	467
202	FDG-PET Evaluation of Response to Treatment. 2008 , 3, 37-75	3
201	Cancer of the Esophagus and Stomach. 2008 , 83, 712-722	9
200	Assessment of treatment response and recurrence in esophageal carcinoma based on tumor length and standardized uptake value on positron emission tomography-computed tomography. 2008 , 86, 1131-8	39
199	[Do locally advanced esophageal cancer still need surgery?]. 2008 , 12, 831-6	3
198	[Use of PET for staging, treatment evaluation, and follow-up in esophageal cancers]. 2008 , 12, 633-9	2

197	PET and PET/CT in the Diagnosis and Staging of Esophageal and Gastric Cancers. 2008 , 3, 135-45	4
196	PET imaging for Treatment Response in Cancer. 2008 , 3, 101-109	3
195	Esophageal cancer: current and emerging therapy modalities. 2008 , 8, 1433-48	41
194	Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. 2008 , 8, 1953-64	3
193	Malignant Tumors of the Esophagus. 2008 , 827-839	
192	Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT. 2008 , 247, 189-96	152
191	Cancer of the Esophagus and Stomach. 2008 , 83, 712-722	54
190	Clinical Utility of Combined 18F-Fluoro-2-deoxyglucose Positron Emission Tomography [Computed Tomography in the Evaluation of Gastrointestinal Malignancies. 2008 , 4, 255-269	4
189	Modern staging and utility of PET imaging in esophageal cancer management. 2008 , 6, 862-9	3
188	[Imaging in oncology and international rules for evaluation: the nuclear medicine]. 2009 , 96, 1127-37	
187	A region growing method for tumor volume segmentation on PET images for rectal and anal cancer patients. 2009 , 36, 4349-58	82
186	FDG-PET/CT imaging predicts histopathologic treatment responses after the initial cycle of neoadjuvant chemotherapy in high-grade soft-tissue sarcomas. 2009 , 15, 2856-63	148
185	Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. 2009 , 29, 403-21	136
184	Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. 2009 , 35, 699-705	21
183	18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer. 2009 , 50 Suppl 1, 89S-96S	81
182	Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. <i>Journal of Clinical Oncology</i> , 2009 , 27, 535-41	2.2 170
181	Tumor budding in tumor invasive front predicts prognosis and survival of patients with esophageal squamous cell carcinomas receiving neoadjuvant chemotherapy. 2009 , 115, 3324-34	91
180	Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. 2009 , 36, 735-44	49

179	Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?. 2009 , 24, 886-95	8
178	Response to preoperative therapy in upper gastrointestinal cancers. 2009 , 16, 878-86	23
177	Positron emission tomography for monitoring response to neoadjuvant therapy in patients with oesophageal and gastro-oesophageal junction carcinoma. 2009 , 35, 1019-29	13
176	The influence of (18)flourodeoxyglucose positron emission tomography on the management of gastroesophageal junction carcinoma. 2009 , 197, 308-12	14
175	Evaluation of the therapeutic effects and recurrence for head and neck cancer after chemoradiotherapy by FDG-PET. 2009 , 36, 192-8	15
174	From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. 2009 , 50 Suppl 1, 122S-50S	2458
173	The role of FDG-PET and staging laparoscopy in the management of patients with cancer of the esophagus or gastroesophageal junction. 2009 , 38, 105-20, ix	9
172	Proteomic and metabolic prediction of response to therapy in gastrointestinal cancers. 2009 , 6, 170-83	15
171	Monitoring response to therapeutic interventions in patients with cancer. 2009 , 39, 210-32	31
170	Role of neoadjuvant therapy for esophageal adenocarcinoma. 2009 , 18, 533-46	11
169	Preoperative therapy for esophageal cancer. 2009 , 38, 135-52, ix	12
168	Impact of fluorodeoxyglucose PET on the management of esophageal cancer. 2009 , 30, 95-116	10
167	NCCN task force: clinical utility of PET in a variety of tumor types. 2009 , 7 Suppl 2, S1-26	76
166	Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma. 2009 , 4, 875-9	62
165	Cancer drug development with the help of radiopharmaceuticals: academic experience. 2009 , 15, 950-6	5
164	[18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer. 2009 , 250, 888-94	91
163	F-18-fluorodeoxiglucose positron emission tomography for the evaluation of neoadjuvant therapy response in esophageal cancer. 2010 , 252, 412-3; author reply 413	2
162	Identifying the Minimum Number of Lymph Nodes Required to Ensure Adequate pN Staging: Kaplan-Meier Survival Analysis Versus Cox Regression Model. 2010 , 252, 411-412	

161	F-18-Fluorodeoxyglucose Positron Emission Tomography for the Evaluation of Neoadjuvant Therapy Response in Esophageal Cancer. 2010 , 252, 413	1
160	Sentinel lymph node biopsy in esophageal cancer: has its time come?. 2010 , 252, 413-4; author reply 415	5
159	Enhanced Recovery After Surgery (ERAS) protocols must be considered when determining optimal perioperative care in colorectal surgery. 2010 , 252, 409; author reply 409-10	6
158	Sentinel Lymph Node Biopsy in Esophageal Cancer: Has Its Time Come?. 2010 , 252, 415	1
157	Identifying the minimum number of lymph nodes required to ensure adequate pN staging: Kaplan-Meier survival analysis versus Cox regression model. 2010 , 252, 410-1; author reply 411-2	2
156	Enhanced Recovery After Surgery (ERAS) Protocols Must Be Considered When Determining Optimal Perioperative Care in Colorectal Surgery. 2010 , 252, 409-410	
155	Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma. 2010 , 5, 713-8	13
154	Whole body 18F-FDG PET predicts progression free and overall survival in squamous cell carcinoma of the esophagus: results of a prospective trial. 2010 , 3, 179-84	6
153	(18)F-fluorodeoxyglucose positron emission tomography immediately after chemoradiotherapy predicts prognosis in patients with locoregional postoperative recurrent esophageal cancer. 2010 , 15, 184-90	17
152	Ösophaguskarzinom: Diagnostik und Response-Prognostik. 2010 , 16, 471-487	
151	Ovarian mass mimicking malignancy: a case report. 2010 , 44, 290-3	9
150	Risk stratification for recurrence in patients with esophageal and junctional carcinoma treated with neoadjuvant chemotherapy and surgery. 2010 , 27, 242-8	6
149	Utility of response evaluation to neo-adjuvant chemotherapy by (18)F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma. 2010 , 148, 908-18	29
148	. 2010 ,	15
147	The Role of Molecular Imaging in Evaluating Tumor Response to Targeted Radiotherapy. 2010 , 527-542	
146	Predicting response to treatment in gastroesophageal junction adenocarcinomas: combining clinical, imaging, and molecular biomarkers. 2010 , 15, 270-84	20
145	68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. 2010 , 51, 1349-56	162
144	FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after Neoadjuvant Therapy in Adult Primary Bone Sarcomas. 2010 , 2010, 143540	22

143	New trends for staging and therapy for localized gastroesophageal cancer: the role of PET. 2010 , 21 Suppl 7, vii294-9	18
142	18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours. 2010 , 65, 291-9	10
141	Prediction of tumor response to neoadjuvant therapy in patients with esophageal cancer with use of 18F FDG PET: a systematic review. 2010 , 254, 707-17	125
140	Handbook of Evidence-Based Radiation Oncology. 2010 ,	32
139	Gastrointestinal Oncology. 2011 ,	
138	PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. 2011 , 36, 526-32	27
137	Modern approaches to localized cancer of the esophagus. 2011 , 9, 902-11	6
136	SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus. 2011 , 11, 466	37
135	Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas. 2011 , 21, 2396-407	6
134	FDG-PET parameters as prognostic factor in esophageal cancer patients: a review. 2011 , 18, 3338-52	56
133	Quantitative assessment of diffusion-weighted MR imaging in patients with primary rectal cancer: correlation with FDG-PET/CT. 2011 , 13, 1020-8	65
132	[Positron emission tomography - current role in the diagnosis and treatment of upper gastrointestinal carcinomas]. 2011 , 136, 1061-6	1
131	Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. 2011 , 52, 369-78	522
130	Retrospective review of patients with locally advanced esophageal cancer treated at the University of Pittsburgh. 2011 , 34, 587-92	3
129	(18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: the MUNICON II trial. 2011 , 52, 1189-96	134
128	Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation:a systematic review and meta-analysis. 2012 , 85, e694-701	35
127	Locally advanced cancer of the esophagus, current treatment strategies, and future directions. 2012 , 2, 52	3
126	Positron emission tomography/computed tomography and esophageal cancer in the clinical practice: How does it affect the prognosis?. 2012 , 8, 619-25	6

125	Positron emission tomography in neoplasms of the digestive system. 2012 , 20, 86-93	
124	Current therapeutic approaches to localized carcinoma of the esophagus and gastroesophageal junction. 2012 , 9, 463-471	
123	PET staging of mediastinal lymph nodes in thoracic oncology. 2012 , 22, 161-6	4
122	¹⁸ F-fluorodeoxyglucose positron emission tomography after definitive chemoradiotherapy in patients with oesophageal carcinoma. 2012 , 44, 875-9	6
121	Esophageal Cancer. 2012 , 211-230	
120	Early Gastrointestinal Cancers. 2012 ,	
119	FDG-PET Parameters as Prognostic Factor in Esophageal Cancer Patients: A Review. 2012 , 3, 330-344	0
118	Esophagus. 174-200	
117	Current treatment options for the management of esophageal cancer. 2012 , 4, 367-77	23
116	Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. 2012 , 118, 2820-7	56
115	Accuracy of PET-CT in predicting survival in patients with esophageal cancer. 2012 , 36, 1089-95	22
114	Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. 2013 , 17, 1359-69	13
113	Curative treatment of esophageal cancer; an evidenced based review. 2013 , 44, 375-84	19
112	Multimodal treatment of esophageal cancer. 2013 , 398, 177-87	36
111	Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours. 2013 , 40, 290-301	119
110	Chemoradiation for esophageal cancer. 2013 , 23, 551-8	15
109	Biomarkers in Oncology. 2013 ,	1
108	Positron emission tomography imaging for gastroesophageal junction tumors. 2013 , 23, 10-5	17

107	Locally Advanced Esophageal Cancer. 2013 ,	
106	Esophageal Cancer: Treatment?. 2014 ,	
105	Value of CT-PET after neoadjuvant chemoradiation in the prediction of histological tumour regression, nodal status and survival in oesophageal adenocarcinoma. 2014 , 101, 1702-11	39
104	18F-fluorodeoxyglucose PET/computed tomography and risk stratification after neoadjuvant treatment in esophageal cancer patients. 2014 , 35, 160-8	4
103	Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET). 2014 , 21, 575-82	23
102	Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma. 2014 , 41, 2008-16	37
101	A systematic review of the predictive value of (18)FDG-PET in esophageal and esophagogastric junction cancer after neoadjuvant chemoradiation on the survival outcome stratification. 2014 , 18, 894-905	41
100	(18)F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer. 2014 , 28, 295-303	17
99	[Not Available]. 2015 , 53, 1288-347	34
98	Staging of esophageal adenocarcinoma by CT, PET, and other modalities. 2015 , 125-136	
97	Combined modality therapy in locally advanced esophageal cancer. 2015 , 221-230	
96	Prospective evaluation of 18F-fluorodeoxyglucose positron emission tomography in patients receiving hepatic arterial and systemic chemotherapy for unresectable colorectal liver metastases. 2015 , 17, 644-50	3
95	. 2015 ,	1
94	Prognostic Factors in Patients Treated with 223Ra: The Role of Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT in Predicting Overall Survival. 2015 , 56, 1177-84	95
93	Prognostic Value of the Maximum Standardized Uptake Value on Positron Emission Tomography for Esophageal Squamous Cell Carcinoma. 2015 , 63, 341-8	3
92	FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer. 2015 , 16, e111-9	13
91	Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1737-44	2.2 30
90	Myocardial metastasis from oesophageal cancer. 2015 , 16 Suppl 2, S71-3	2

89	Esophageal Cancer. 2015 ,	1
88	Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma. 2015 , 149, 1700-15	327
87	Potential impact of (18)FDG-PET/CT on surgical approach for operable squamous cell cancer of middle-to-lower esophagus. 2016 , 9, 855-62	2
86	Circulating Tumor Cells in the Adenocarcinoma of the Esophagus. 2016 , 17,	9
85	Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. 2016 , 122, 2083-90	23
84	The 100 most cited articles investigating the radiological staging of oesophageal and junctional cancer: a bibliometric analysis. 2016 , 7, 619-28	6
83	PET/CT in Oesophageal and Gastric Cancer. 2016 ,	
82	Clinical Significance of FDG-PET to Predict Pathologic Tumor Invasion and Lymph Node Metastasis of Superficial Esophageal Squamous Cell Carcinoma. 2016 , 23, 4086-4092	10
81	Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers. 2017 , 26, 241-256	1
80	Identification of Metabolic Biomarkers Using Serial F-FDG PET/CT for Prediction of Recurrence in Advanced Epithelial Ovarian Cancer. 2017 , 10, 297-303	2
79	Importance of positron emission tomography for assessing the response of primary and metastatic lesions to induction treatments in T4 esophageal cancer. 2017 , 162, 836-845	16
78	PET/Computed Tomography Scanning and Precision Medicine: Esophageal Cancer. 2017 , 12, 373-391	13
77	Developments in optical imaging for gastrointestinal surgery. 2017 , 13, 2363-2382	1
76	Impact on Radiological and Pathological Response with Neoadjuvant Chemoradiation and Its Effect on Survival in Squamous Cell Carcinoma of Thoracic Esophagus. 2017 , 48, 42-49	7
75	Prospective Evaluation of Changes in Tumor Size and Tumor Metabolism in Patients with Advanced Gastric Cancer Undergoing Chemotherapy: Association and Clinical Implication. 2017 , 58, 899-904	13
74	Esophageal Cancer. 2018 , 33-53	
73	Neoadjuvant chemoradiation for esophageal cancer : Surgery improves locoregional control while response based on FDG-PET/CT predicts survival. 2018 , 194, 435-443	5
72	Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma. 2018 , 267, 898-904	8

71	Staging of Esophageal Cancer: Implications for Therapy. 2018 , 29-43	0
70	Esophageal Cancer. 2018 ,	1
69	Imaging and Staging of Esophageal Cancers. 2018 , 263-278	
68	. 2019 , 57, 336-418	10
67	18 Gastric, Esophageal, and Gastrointestinal Stromal Tumors. 2019 ,	
66	Application of positron emission tomography imaging to personalize esophagogastric cancer care. 2019 , 125, 1214-1217	2
65	Post-chemoradiotherapy FDG PET with qualitative interpretation criteria for outcome stratification in esophageal squamous cell carcinoma. 2019 , 14, e0210055	9
64	Prognostic values of mid-radiotherapy F-FDG PET/CT in patients with esophageal cancer. 2019 , 14, 27	11
63	Isocitrate dehydrogenase gene mutations and 2-hydroxyglutarate accumulation in esophageal squamous cell carcinoma. 2018 , 36, 11	4
62	Endoscopic Ultrasound in Esophageal and Gastric Cancer. 2019 , 79-99.e8	
61	Association of the primary tumor's SUVmax with survival after surgery for clinical stage IA esophageal cancer: a single-center retrospective study. 2020 , 25, 561-569	3
60	Cancer of the Esophagus. 2020 , 1174-1196.e6	
59	Esophageal Cancer. 2020 ,	0
58	Novel 5-point 18-FDG-PET/CT visual scoring system for assessing treatment response in patients with oesophageal or gastro-oesophageal junction carcinoma. 2021 , 65, 23-37	
57	Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of oesophageal cancer. 2021 , 15, 1195	
56	Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography. 2012 , 196, 201-11	13
55	CHEMOTHERAPY AND RADIOTHERAPY AS PRIMARY TREATMENT OF ESOPHAGEAL CANCER. 2008 , 509-526	1
54	Preoperative Chemo-Radiation-Induced Ulceration in Patients with Esophageal Cancer: A Confounding Factor in Tumor Response Assessment in Integrated Computed Tomographic-Positron Emission Tomographic Imaging. 2006 , 1, 478-486	46

53	Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. 2017 , 8, 30477-30494		14
52	Esophageal cancer: staging system and guidelines for staging and treatment. <i>Journal of Thoracic Disease</i> , 2014 , 6 Suppl 3, S289-97	2.6	71
51	Current strategies in chemoradiation for esophageal cancer. 2014 , 5, 156-65		35
50	State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment. 2015 , 6, 3-19		22
49	Endoscopic options for early stage esophageal cancer. 2015 , 6, 20-30		27
48	Using positron-emission tomography-computed tomography for predicting radiotherapy-induced tumor regression in carcinoma esophagus in an Indian population. 2019 , 18, 361-365		2
47	Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. 2014 , 6, 112-20		462
46	The value of 18 F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy. 2012 , 156, 171-9		14
45	DIAGNOSIS AND STAGING OF ESOPHAGEAL CANCER. 2008 , 454-463		1
44	Cancer of the Esophagus. 2008 , 1399-1429		
43	Positron Emission Tomography/Computed Tomography of the Hollow Viscera. 2008 , 107-116		
42	Video-Assisted Thoracic Surgery. 2008 , 1535-1549		
41	NUCLEAR IMAGING. 2008 , 85-96		
40	Esophageal Cancer. 2008 , 108-126		1
39	PET/CT in Abdominal and Pelvic Malignancies: Principles and Practices. 2008 , 166-208		
38	Positron emission tomography's changing significance in the treatment of esophageal cancer. 2009 , 1, 34-7		
37	Staging Techniques for Carcinoma of the Esophagus. 2010 , 577-587		
36	Esophageal Cancer. 2010 , 315-330		

- 35 Pelvis. **2010**, 393-417
- 34 Imaging in Radiation Oncology * *This chapter is an update and expansion of material presented in the first edition by C.C. Ling, R. Mohan, L.E. Reinstein, and L.N. Rothenberg, and in the second edition by the current authors.. **2010**, 120-154
- 33 Esophageal Cancer. **2011**, 67-100
- 32 Imaging in Gastrointestinal Cancer. **2011**, 1-20
- 31 Surrogate Markers: The Role of Positron Emission Tomography Scanning. **2013**, 275-296
- 30 Cancers of the Esophagus and Small Bowel, Precancerous States of the Large Bowel, and Gastrointestinal Stromal Tumors. **2013**, 423-450
- 29 Cancer of the Esophagus. **2014**, 1207-1239.e7
- 28 Diagnostic Imaging of the Esophageal Cancer. **2015**, 33-61
- 27 The Multidisciplinary Management of Early Distal Esophageal and Gastroesophageal Junction Cancer. **2015**, 203-220
- 26 The Multidisciplinary Management of Early-Stage Thoracic Esophageal Cancer. **2015**, 187-201
- 25 FDG-PET/CT in Oesophageal and Gastric Cancer. **2016**, 79-90
- 24 Focal Hepatic Fluorodeoxyglucose Uptake Mimics Liver Metastasis Following External Beam Radiation for Gastroesophageal Cancers: A Case and Review of the Literature. **2016**, 6, 30
- 23 Neoadjuvant and Adjuvant Therapy. **2018**, 55-63
- 22 The Multidisciplinary Management of Early-Stage Thoracic Esophageal Cancer. **2020**, 237-250
- 21 The Multidisciplinary Management of Early Distal Esophageal and Gastroesophageal Junction Cancer. **2020**, 251-273
- 20 Clinical relevance of fluorodeoxyglucose positron emission tomography/computed tomography and magnifying endoscopy with narrow band imaging in decision-making regarding the treatment strategy for esophageal squamous cell carcinoma. *World Journal of Gastroenterology*, **2019**, 25, 6767-6780 5.6 0
- 19 Diagnostic Imaging of the Esophageal Cancer. **2020**, 35-61 1
- 18 Esophageal Carcinoma. **2005**, 106-114

- 17 Positron Emission Tomography and Cancer. **2006**, 449-483
- 16 PET and PET/CT Imaging in Esophageal and Gastric Cancers. **2006**, 165-180
- 15 Esophageal Cancer: Initial Staging. **2008**, 83-95
- 14 [18F]Fluorodeoxyglucose Positron Emission Tomography Assessment of Response. **2007**, 103-120 1
- 13 Esophageal and Gastric Cancer. **2007**, 72-92
- 12 Basis of Tumor Imaging 2: Scintigraphic and Pathophysiologic Correlation. **2006**, 278-304
- 11 Diagnosis of Barrett's Carcinoma: Role of Diagnostic Imaging. **2021**, 135-150
- 10 Diabetes and PET Scans: Only Part of a Bigger Problem. *Gastrointestinal Cancer Research: GCR*, **2009**, 3, 165-6
- 9 Decreased Posttreatment SUV on PET Scan Is Associated With Improved Local Control in Medically Inoperable Esophageal Cancer. *Gastrointestinal Cancer Research: GCR*, **2011**, 4, 84-9 2
- 8 Positron Emission Tomography's Utility in Esophageal Cancer Management. *Journal of Thoracic Disease*, **2009**, 1, 29-33 2.6 5
- 7 Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. *Gastrointestinal Cancer Research: GCR*, **2012**, 5, 85-92 4
- 6 Tratamiento del cáncer de esófago localizado y localmente avanzado: ¿algo ha cambiado?. **2003**, 5, 239-248
- 5 Significance of mid-radiotherapy 18F-fluorodeoxyglucose positron emission tomography/computed tomography in esophageal cancer.. *Radiotherapy and Oncology*, **2022**, 5-3
- 4 Positron Emission Tomography and Computed Tomography of the Hollow Viscera. **2015**, 96-111
- 3 Prognostic Assessment of Interim F18-Fluorodeoxyglucose Positron Emission Tomography in Esophageal Cancer Treated With Chemoradiation With or Without Surgery. **2022**, 0
- 2 The prognostic value of positron emission tomography/computed tomography-based parameters in locally advanced esophageal squamous cell carcinoma treated with chemoradiation therapy. **2022**, 43, 1239-1246 0
- 1 Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma. **2023**, 33, 3647-3659 0